Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.35 |
| ▸ | S1PR3 | Q99500 | 7/20 | 0.34 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.32 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.32 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29932195 | 1.00 | KMT2A (0.36) | KMT2ACYP11B1CYP11B2PTGDR2S1PR3 | |
| SCHEMBL1544963 | 0.84 | PTGDR2 (0.36) | KMT2APTGDR2TP53CYP3A4TSHR | |
| SCHEMBL6212336 | 0.77 | PTGDR2 (0.38) | KMT2ACYP11B1CYP11B2PTGDR2S1PR3 | |
| SCHEMBL496891 | 0.77 | TRPV4 (0.57) | CYP11B1CYP11B2S1PR3TRPV4VCAM1 | |
| SCHEMBL9996715 | 0.77 | CYP11B1 (0.35) | KMT2ACYP11B1CYP11B2PTGDR2S1PR3 | |
| SCHEMBL434666 | 0.76 | ALDH1A1 (0.42) | CYP11B1CYP11B2PTGDR2TRPV4TDP1 | |
| SCHEMBL30111761 | 0.76 | ALDH1A1 (0.42) | CYP11B1CYP11B2PTGDR2TRPV4TDP1 | |
| SCHEMBL2783347 | 0.76 | TP53 (0.48) | KMT2ATRPV4TP53CYP3A4TSHR | |
| SCHEMBL19859678 | 0.76 | ESR1 (0.42) | CYP11B1CYP11B2 | |
| SCHEMBL16182687 | 0.74 | HDAC8 (0.34) | CYP11B1CYP11B2TRPV4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1551834-B1 | SUBSTITUTED QUINAZOLINONE COMPOUNDS | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2010-08-25 | — | — | EP | claimed |
| US-12528781-B2 | Heterocyclic GLP-1 agonists | GASHERBRUM BIO, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| EP-4638455-A1 | HETEROCYCLIC GLP-1 AGONISTS | Gasherbrum Bio, Inc. (US) | 2025-10-29 | — | — | EP | disclosed |
| EP-4192831-B1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO INC (US) | 2025-10-22 | — | — | EP | disclosed |
| US-20250145596-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2025-05-08 | — | — | US | disclosed |
| WO-2025034034-A1 | NOVEL COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF CANCER OR TUMORS COMPRISING SAME | 주식회사 대웅제약 | 2025-02-13 | — | — | WO | disclosed |
| EP-4476213-A1 | HETEROCYCLIC GLP-1 AGONISTS | Gasherbrum Bio, Inc. (US) | 2024-12-18 | — | — | EP | disclosed |
| CN-119072474-A | Heterocyclic GLP-1 agonists | 加舒布鲁姆生物公司 | 2024-12-03 | — | — | CN | disclosed |
| US-20240376061-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2024-11-14 | — | — | US | disclosed |
| US-12024507-B2 | Compounds as GLP-1R agonists | TERNS PHARMACEUTICALS, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| WO-2013186692-A1 | TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-12-19 | — | — | WO | disclosed |
| WO-2013186692-A1 | TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-12-19 | — | — | WO | disclosed |
| EP-1650284-B1 | Liquid crystal composition containing an optical active compound and liquid crystal electro-optical element | SEIMI CHEM KK (JP) | 2008-04-30 | — | — | EP | disclosed |
| US-7108895-B2 | Liquid crystal composition containing an optically active compound and liquid crystal electro-optical element | SEIMI CHEMICAL CO., LTD. (JP) | 2006-09-19 | — | — | US | disclosed |
| EP-1650284-A2 | Liquid crystal composition containing an optical active compound and liquid crystal electro-optical element | Seimi Chemical Co., Ltd. (JP) | 2006-04-26 | — | — | EP | disclosed |
| EP-1650285-A2 | Liquid crystal composition containing an optically active compound and liquid crystal electro-optical element | Seimi Chemical Co., Ltd. (JP) | 2006-04-26 | — | — | EP | disclosed |
| EP-1650286-A2 | Liquid crystal composition containing an optically active compound and liquid crystal electro-optical element | Seimi Chemical Co., Ltd. (JP) | 2006-04-26 | — | — | EP | disclosed |
| US-20040079922-A1 | Liquid crystal composition containing an optically active compound and liquid crystal electro-optical element | SEIMI CHEMICAL CO., LTD. (JP) | 2004-04-29 | — | — | US | disclosed |
| EP-1371712-A1 | LIQUID-CRYSTAL COMPOSITION CONTAINING OPTICALLY ACTIVE COMPOUND AND LIQUID-CRYSTAL ELECTROOPTIC ELEMENT | Seimi Chemical Co., Ltd. (JP) | 2003-12-17 | — | — | EP | disclosed |
| WO-1997009881-A1 | HERBICIDAL MIXTURES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1997-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12024507-B2 | Compounds as GLP-1R agonists | GLP1R, GIPR, GCGR | KMT2A 4554/4885CYP11B1 1832/4885CYP11B2 2503/4885 |
| US-12528781-B2 | Heterocyclic GLP-1 agonists | GLP1R, GIPR, VIP | KMT2A 3022/4885CYP11B1 1495/4885CYP11B2 1987/4885 |
| US-20250145596-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | KMT2A 3661/4885CYP11B1 917/4885CYP11B2 1402/4885 |
| US-20240376061-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | KMT2A 4112/4885CYP11B1 1049/4885CYP11B2 1797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.